A hot biotech that may be the next Genentech
May 12, 2015 at 07:00 AM EDT
This company has raised $1 billion to develop the Holy Grail in drugs: having the body's own cells churn out proteins to fight disease.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.